The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease ...

Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjögren's ...

The Work and Pensions Secretary has announced plans to tighten the eligibility criteria for Personal Independence Payment ...

Mar. 12, 2025 — Lupus is an autoimmune disease where the body's immune system attacks its own tissues and organs, causing inflammation and damaging organs. A new study has now shown that the ...

This situation puts patients at high risk for organ failure or even death. Furthermore, many patients with SLE have to take long-term, sometimes even life-long immune suppressive medication to control ...

Diagnosis of systemic lupus erythematosus meeting the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria at least 6 months prior to ...

Genome-wide association studies and fine mapping of candidate regions have rapidly advanced our understanding of the genetic basis of systemic lupus erythematosus (SLE). More than 20 robust ...

CERTAIN hypertensive patients treated with hydralazine hydrochloride acquire a clinical picture that, when fully manifested, is indistinguishable from that of systemic lupus erythematosus.

Experts And Viewpoints, June 13, 2000 Ask the Experts - Is There a Risk of Thrombosis in a Patient With SLE... I have a 10-year-old female patient who has systemic lupus erythematosus (SLE ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that causes widespread inflammation. It can affect the skin, joints, blood vessels, and multiple organ systems. The exact cause ...

Reported as titer. Present in 30% (Ro/SS-A) and 15% (La/SS-B) of patients with SLE. These antibodies are also seen in patients with Sjogren's syndrome. Anti-Ro/SS-A alone is more common in SLE ...

The following is a summary of “Prevalence, clinical features, and long-term outcome of patients with primary Sjögren’s syndrome with renal involvement,” published in the February 2025 issue of ...